# Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders

> **NCT05962216** · — · RECRUITING · sponsor: **Dr. Albert Kar-Kin Chung** · enrollment: 40 (estimated)

## Conditions studied

- Psychosis
- Depression

## Interventions

- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT05962216
- **Lead sponsor:** Dr. Albert Kar-Kin Chung
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05962216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05962216, "Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05962216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*